Inhibition of mutationally activated HER2

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Human epidermal growth factor receptor 2 (HER2) is a critical oncogenic driver in various human cancers.
• Current HER2-targeted therapies primarily address wild-type HER2 overexpression.
• Kinase domain mutations can confer hyperactivity to HER2, independent of expression levels.

Purpose of the Study:

• To identify small molecule inhibitors specifically targeting cancer-associated HER2 kinase domain mutants.
• To investigate the inhibitory potential of novel compounds against HER2 variants like D769Y and P780insGSP.

Main Methods:

• Biochemical testing of purified enzymes to confirm mutant HER2 hyperactivity.
• Similarity-based searching and in silico modeling for inhibitor identification.
• In vitro and cell-based assays to evaluate candidate molecule efficacy.

Main Results:

• Confirmed hyperactivity of HER2 mutants D769Y and P780insGSP.
• Identified a candidate small molecule inhibitor effective against mutant HER2.
• Structural modeling suggested water-mediated interactions in the HER2 kinase binding pocket.

Conclusions:

• A novel small molecule inhibitor demonstrates efficacy against mutant HER2 variants.
• This compound represents a promising therapeutic candidate for HER2-mutant driven cancers.
• Targeting HER2 mutants offers a new avenue for cancer treatment beyond HER2 overexpression.